According to a document filed with the U.S. Securities and Exchange Commission, data released by Celcuity Inc shows that its Gedatolisib triplet therapy achieved significant results in a pivotal trial.

According to a document filed with the U.S. Securities and Exchange Commission, data released by Celcuity Inc shows that its Gedatolisib triplet therapy achieved significant results in a pivotal trial.

老虎证券2026/06/02 12:21

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The median progression-free survival of this therapy reached 11.1 months, whereas the control group treated with the Alpelisib combined with Fulvestrant regimen had a median progression-free survival of only 5.6 months. This comparative data highlights the potential advantage of the Gedatolisib triple therapy.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to a document filed with the U.S. Securities and Exchange Commission, data released by Celcuity Inc shows that its Gedatolisib triplet therapy achieved significant results in a pivotal trial.

You may also like

Crypto prices